![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, May 05, 2014 4:45:34 PM
On May 1, 2014, the Company entered into an asset purchase agreement (the “Provista APA”) with Provista Diagnostics, Inc., a Delaware Corporation (“Provista”) pursuant to which the Company purchased certain assets of Provista related to a fluorescently activated cell sorter (“FACS”), including all right, title and interest in the certain assets, equipment, software and technology related to FACS (altogether, the “Assets”).
As consideration for transfer of the Assets pursuant to the Provista APA, the Company shall, upon closing of the Provista APA, pay to Provista a one-time cash payment of $20,000.
I believe this is referring to a BD FACSCalibur machine like this one: www.bdbiosciences.com/instruments/facscalibur/
If AMBS is looking to commercialize LymPro with a CLIA partner (who would bring their own FACS capability), then why are they buying a machine of their own? Do they need to run additional proof-of-concept studies in-house? Do they want to run demos for potential future partners without having to lean on BD or a CLIA lab? Lots of possibilities here...
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM